Kadcyla (trastuzumab emtansine) vs Orserdu (elacestrant)
Kadcyla (trastuzumab emtansine) vs Orserdu (elacestrant)
Kadcyla (trastuzumab emtansine) is a targeted therapy used primarily to treat HER2-positive metastatic breast cancer and is designed to combine the HER2 targeting properties of trastuzumab with the chemotherapy agent DM1; it works by attaching to HER2-positive cancer cells and delivering the chemotherapy directly to them. Orserdu (elacestrant), on the other hand, is a selective estrogen receptor degrader (SERD) indicated for the treatment of estrogen receptor (ER)-positive, HER2-negative advanced or metastatic breast cancer, particularly in postmenopausal women or in men, and it functions by degrading the estrogen receptor, thereby inhibiting the growth of cancer cells that rely on estrogen signals. When deciding between these two medications, it is crucial to consider the specific subtype of breast cancer present, as Kadcyla is appropriate for HER2-positive tumors, while Orserdu is used for ER-positive, HER2-negative tumors, and the decision should be guided by a healthcare professional's assessment of the tumor's receptor status and the patient's overall health condition.
Difference between Kadcyla and Orserdu
Metric | Kadcyla (trastuzumab emtansine) | Orserdu (elacestrant) |
---|---|---|
Generic name | Trastuzumab emtansine | Elacestrant |
Indications | HER2-positive breast cancer | ER+/HER2- advanced or metastatic breast cancer |
Mechanism of action | Antibody-drug conjugate targeting HER2 receptors | Oral selective estrogen receptor degrader (SERD) |
Brand names | Kadcyla | Orserdu |
Administrative route | Intravenous injection | Oral |
Side effects | Fatigue, nausea, musculoskeletal pain, hemorrhage, hepatotoxicity | Hot flush, nausea, fatigue, musculoskeletal pain, increased blood cholesterol |
Contraindications | Hypersensitivity to trastuzumab emtansine or excipients | Hypersensitivity to elacestrant or excipients |
Drug class | Antibody-drug conjugate | Selective estrogen receptor degrader (SERD) |
Manufacturer | Genentech (Roche) | Radiant Pharmaceuticals |
Efficacy
Efficacy of Kadcyla (Trastuzumab Emtansine) in Breast Cancer
Kadcyla (trastuzumab emtansine) is a targeted therapy drug used for the treatment of HER2-positive breast cancer. HER2 is a protein that can promote the growth of cancer cells. In some cancers, notably breast cancer, HER2 is overexpressed, and this overexpression can be associated with increased disease aggressiveness and a poorer prognosis. Kadcyla is designed to target and destroy the cancer cells that have HER2 on their surface. It is typically used in patients who have previously received trastuzumab and a taxane, separately or in combination. Clinical trials have demonstrated that Kadcyla significantly improves progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer compared to standard therapies.
The efficacy of Kadcyla was highlighted in a pivotal phase III clinical trial known as EMILIA. The trial compared Kadcyla to lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer who had previously been treated with trastuzumab and a taxane chemotherapy. The results showed that Kadcyla significantly extended median progression-free survival and overall survival. These findings established Kadcyla as an effective treatment option for patients with this type of breast cancer, particularly in the metastatic setting.
Efficacy of Orserdu (Elacestrant) in Breast Cancer
Orserdu (elacestrant) is a novel oral selective estrogen receptor degrader (SERD) that is being investigated for the treatment of estrogen receptor (ER)-positive breast cancer. ER-positive breast cancer is the most common subtype of breast cancer, where the cancer cells grow in response to the hormone estrogen. Orserdu works by binding to the estrogen receptor, degrading it, and thus inhibiting the receptor's interaction with estrogen. This mechanism can help to slow or stop the growth of ER-positive breast cancer cells.
While Orserdu is still under clinical investigation, early trial results have been promising. In a phase II study, Orserdu showed clinical efficacy in patients with ER-positive, HER2-negative advanced breast cancer who had progressed on prior endocrine therapy and CDK4/6 inhibitors. The study indicated that Orserdu has the potential to be an effective treatment option for this patient population, which often has limited treatment choices after standard therapies fail. As research continues, Orserdu may offer a new hope for patients with ER-positive breast cancer, particularly those with advanced or metastatic disease.
Regulatory Agency Approvals
Kadcyla
Orserdu
Access Kadcyla or Orserdu today
If Kadcyla or Orserdu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us